Triptorelin in the management of prostate cancer

Future Oncology

Volumn 9, Issue 1, 2013, Pages 93-102

  Ploussard, Guillaume ^a,b   Mongiat Artus, Pierre ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c Institut Universitaire d'Hématologie   (France)

Author keywords

androgen deprivation therapy; castration resistance; GnRH agonist; prostate cancer

Indexed keywords

ANDROGEN; DEGARELIX; FOLLITROPIN; GONADORELIN AGONIST; LEUPRORELIN; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLEASON SCORE; HUMAN; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; METASTASIS; ORCHIECTOMY; OVERALL SURVIVAL; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMISTRY, PHARMACEUTICAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; TRIPTORELIN PAMOATE;

EID: 84871431253     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.158     Document Type: Review

References (66)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16(3), 481-488 (2005). (Pubitemid 40458328)
3. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007). (Pubitemid 46359643)
4. Huggins C, Hodges CV. Studies on prostatic cancer 1: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 19, 293-297 (1941).
5. Miller K, Anderson J, Abrahamsson PA. Treatment of prostate cancer with hormonal therapy in Europe. BJU Int. 103(Suppl. 2), S2-S6 (2009).
6. Palmberg C, Koivisto P, Visakorpi T, Tammela TL. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur. Urol. 36(3), 191-196 (1999). (Pubitemid 29381303)
7. Damber JE, Aus G. Prostate cancer. Lancet 371(9625), 1710-1721 (2008). (Pubitemid 351671887)
8. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev. Urol. 7(Suppl. 5), S3-S12 (2005).
9. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 294(2), 238-244 (2005). (Pubitemid 41043794)
10. Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59(4), 572-583 (2011).
11. Barron JL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J. Clin. Endocrinol. Metab. 54(6), 1169-1173 (1982). (Pubitemid 13238696)
12. Limonta P, Montagnani Marelli M, Moretti RM. LHRH analogues as anticancer agents: Pituitary and extrapituitary sites of action. Expert Opin Investig. Drugs 10(4), 709-720 (2001). (Pubitemid 32288188)
13. Schally AV. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis. Peptides 20(10), 1247-1262 (1999). (Pubitemid 29512447)
14. Martin-Merino E, Johansson S, Morris T, Garcia Rodriguez LA. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: A nested caseYcontrol study in UK primary care. Drug Saf. 34(11), 1061-1077 (2011).
15. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int. 92(3), 226-231 (2003). (Pubitemid 36966582)
16. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group Phase III study in patients with prostate cancer. BJU Int. 102(11), 1531-1538 (2008).
17. Crawford ED, Tombal B, Miller K et al. A Phase III extension trial with a 1-arm crossover from leuprolide to degarelix: Comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186(3), 889-897 (2011).
18. Seidenfeld J, Samson DJ, Hasselblad V et al. Single-therapy androgen suppression in men with advanced prostate cancer: A systematic review and meta-analysis. Ann. Intern. Med. 132(7), 566-577 (2000). (Pubitemid 30171897)
19. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): An open randomised Phase III trial. Lancet 373(9660), 301-308 (2009).
20. Bolla M, de Reijke TM, Van Tienhoven G et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360(24), 2516-2527 (2009).
21. Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma Y long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1285-1290 (2005). (Pubitemid 40470408)
22. Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N. Engl. J. Med. 365(2), 107-118 (2011).
23. Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 12(5), 451-459 (2011).
24. Ploussard G, Masson-Lecomte A, Beauval JB et al. Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: Oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification. Urology 78(3), 607-613 (2011).
25. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76(3), 710-714 (2010).
26. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst. Rev. (4), CD006019 (2006).
27. Messing EM, Manola J, Yao J et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7(6), 472-479 (2006). (Pubitemid 43779173)
28. Sumey C, Flaig TW. Adjuvant medical therapy for prostate cancer. Expert Opin Pharmacother. 12(1), 73-84 (2011).
29. Dorff TB, Flaig TW, Tangen CM et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J. Clin. Oncol. 29(15), 2040-2045 (2011).
30. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making. Urology 56(6), 1021-1024 (2000).
31. Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J. Urol. 178(4 Pt 1), 1290-1295 (2007). (Pubitemid 47368393)
32. Perachino M, Cavalli V, Bravi F Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: Prognostic significance? BJU Int. 105(5), 648-651 (2010).
33. Novara G, Galfano A, Secco S, Ficarra V, Artibani W. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol. Int. 82(3), 249-255 (2009).
34. Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: Mechanisms of castration resistance and therapeutic implications. Best Pract. Res. Clin. Endocrinol. Metab. 22(2), 243-258 (2008). (Pubitemid 351611949)
35. Klotz L, O'Callaghan CJ, Ding K et al. A Phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/ SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J. Clin. Oncol. 29(Suppl. 7), Abstract 3 (2011).
36. Amaral TM, Macedo D, Fernandes I, Costa L. Castration-resistant prostate cancer: Mechanisms, targets, and treatment. Prostate Cancer 2012, 327253 (2012).
37. Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br. J. Cancer 95(7), 767-774 (2006). (Pubitemid 44498089)
38. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
39. Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur. Urol. 53(5), 890-900 (2008).
40. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death. Int. J. Radiat. Oncol. Biol. Phys. 75(1), 10-15 (2009).
41. Manni A, Bartholomew M, Caplan R et al. Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome. J. Clin. Oncol. 6(9), 1456-1466 (1988). (Pubitemid 19089035)
42. Braga-Basaria M, Dobs AS, Muller DC et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J. Clin. Oncol. 24(24), 3979-3983 (2006). (Pubitemid 46630747)
43. Smith MR, Lee H, McGovern F et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 112(10), 2188-2194 (2008). (Pubitemid 351628628)
44. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer 113(12), 3290-3297 (2008).
45. D'Amico AV, Denham JW, Crook J et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J. Clin. Oncol. 25(17), 2420-2425 (2007). (Pubitemid 46999213)
46. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24(27), 4448-4456 (2006). (Pubitemid 46630983)
47. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110(7), 1493-1500 (2007). (Pubitemid 47463063)
48. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J. Natl Cancer Inst. 99(20), 1516-1524 (2007). (Pubitemid 351767235)
49. Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur. Urol. 54(4), 816-823 (2008).
50. Efstathiou JA, Bae K, Shipley WU et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol. 27(1), 92-99 (2009).
51. Roach M 3rd, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J. Clin. Oncol. 26(4), 585-591 (2008). (Pubitemid 351264352)
52. Studer UE, Whelan P, Albrecht W et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J. Clin. Oncol. 24(12), 1868-1876 (2006). (Pubitemid 46638985)
53. Levine GN, D'Amico AV, Berger P et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation 121(6), 833-840 (2010).
54. Nguyen PL, Je Y, Schutz FA et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 306(21), 2359-2366 (2011).
55. Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int. 100(4), 738-743 (2007). (Pubitemid 47360177)
56. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 52(6), 1598-1605 (1992).
57. Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised Phase 3 study of the South European Uroncological Group. Eur. Urol. 55(6), 1269-1277 (2009).
58. Hussain M, Tangen CM, Higano CS et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international Phase III trial. J. Clin. Oncol. 30, Abstract 4 (2012).
59. Shaheen JA, Amin M, Harty JI. Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist. Urology 42(5), 533-535 (1993). (Pubitemid 23347266)
60. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer. Eur. Urol. 30(Suppl. 1), S7-S14; discussion 19-21 (1996).
61. de Jong IJ, Eaton A, Bladou F. LHRH agonists in prostate cancer: Frequency of treatment, serum testosterone measurement and castrate level: Consensus opinion from a roundtable discussion. Curr. Med. Res. Opin 23(5), 1077-1080 (2007). (Pubitemid 46799591)
62. Kuhn JM, Abourachid H, Brucher P et al. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur. Urol. 32(4), 397-403 (1997). (Pubitemid 27501035)
63. Abbou CC, Lucas C, Leblanc V. Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer. Prog. Urol. 7(6), 984-995 (1997). (Pubitemid 127525587)
64. Teillac P, Heyns CF, Kaisary AV, Bouchot O, Blumberg J. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm. Res. 62(5), 252-258 (2004). (Pubitemid 39551740)
65. Mounedji N, Lundstrom EA, Purcea D, Grosgurin P, Porchet HC. Efficacy of triptorelin in lowering serum testosterone (sT) in patients with advanced prostate cancer. J. Clin. Oncol. 29(Suppl. 7), Abstract 162 (2011).
66. Lundstrom EA, Rencken RK, van Wyk JH et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: An open-label, non-comparative, multicentre, Phase III study. Clin. Drug Investig. 29(12), 757-765 (2009).